Item 7.01. Regulation FD Disclosure.

On January 13, 2023, Jasper Therapeutics, Inc. issued a press release announcing that new positive data for briquilimab (formerly known as JSP191) will be presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR taking place on February 15-19, 2023 in Orlando, Florida. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01, including the press release attached hereto as Exhibit 99.1, is being furnished under Item 7.01 of Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.





(d) Exhibits.



Exhibit No.   Description
   99.1         Press Release, dated January 13, 2023.
    104       Cover Page Interactive Data File, formatted in Inline Extensible
              Business Reporting Language (iXBRL).




                                       1

© Edgar Online, source Glimpses